PT
Protagonist
PTGX·NASDAQNewark CAFounded 2006120 employees
Mid CapbiotechPublicHematologyGI
Platform: Peptide
Market Cap
$3.5B
All Drugs
3
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (PTGX)
Loading PTGX stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Talatuximab | PTG-369 | Phase 2 | 1 | B7-H3 | NMOSD | ||
| Mavuzasiran | PTG-7591 | Phase 3 | 4 | MET | Rett | ||
| Motatinib | PTG-5322 | Preclinical | 1 | MDM2 | Bladder CaHCC |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (5)